Cancer is daunting for both patients and for clinical teams. Dr John McGrane and Dr Michael Rowe are oncologists who want to break down the complex parts of cancer care into clear and simple sessions.
We will dive deep into the world of cancer research, patient stories and the latest cancer breakthroughs. Simply Oncology will have patient focused episodes along with episodes that allow anyone with an interest in oncology to stay up to date. We hope you join us as we unpick all parts of cancer.
Oncology, gynaecology and primary-care teams get survivorship guidance for menopause after cancer treatment. It covers active symptom screening, tumour-specific HRT risk assessment, post-treatment review, bone health, lifestyle measures and clear oncology input when ongoing prescribing moves into primary care.
Oncology, gynaecology and menopause-care clinicians get a symptom-led approach to cancer treatment-induced menopause. Ovarian surgery, chemotherapy or pelvic radiotherapy may cause vasomotor, sleep, mood, sexual, urogenital, fatigue and cognitive symptoms requiring individualised HRT, vaginal oestrogen or non-hormonal decisions.
Oncology and gynaecology teams get a treatment-sequencing update for platinum-resistant ovarian cancer. Folate receptor alpha testing, mirvetuximab soravtansine, ocular toxicity, immunotherapy combinations, glucocorticoid receptor antagonism, response need and time toxicity all shape patient-centred decisions.
Oncology clinicians and educators get a practical framework for explaining treatment benefit, recurrence and toxicity. It prioritises absolute risk, natural frequencies, common denominators, visual aids and teach-back while keeping frailty, competing mortality, quality of life and patient goals within shared decision-making.
For neuro-oncology teams, glioblastoma gene therapy brings tumour heterogeneity into trial conversations. This links TGX-007, ADePT, convection-enhanced delivery, tissue endpoints and early phase safety monitoring without assuming that striking mouse survival results translate directly to humans.
Pancreatic radiotherapy decisions need selection, local-control goals and toxicity planning made explicit. SABR and adaptive image guidance sit close to stomach, duodenum, bowel and vasculature, so pain, nausea, bleeding, perforation, diabetes and malabsorption require planned review.
Pancreatic cancer radiotherapy is presented as palliation, consolidation after systemic therapy, neoadjuvant treatment in selected borderline resectable disease and possible oligometastatic control. The clinical decision is selection: metastatic status, chemotherapy response, luminal gastrointestinal invasion, nutritional burden and realistic treatment goals.
Metastatic renal cell carcinoma is told through a patient-centred lens here. Pick this for immunotherapy conversations, ipilimumab–nivolumab response, nephrectomy when a kidney tumour continues bleeding, surveillance uncertainty and how valued activities can shape shared decision-making.
Adjuvant kidney cancer treatment is for patients who may already be disease-free, so uncertainty matters. The discussion separates recurrence risk, disease-free survival, overall survival uncertainty, relapse timing after pembrolizumab and belzutifan toxicity, especially anaemia and hypoxia.
Adjuvant kidney cancer decisions need recurrence risk made visible. Use stage, grade, nodal status and recurrence-risk score before offering pembrolizumab, and state the uncertainty for non-clear cell disease rather than stretching clear cell trial data.
.svg)